Skm Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 30-07-2024
- Paid Up Capital ₹ 7.50 M
as on 30-07-2024
- Company Age 37 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.40 M
as on 30-07-2024
- Satisfied Charges ₹ 4.50 Cr
as on 30-07-2024
- Revenue -13.98%
(FY 2023)
- Profit 185.74%
(FY 2023)
- Ebitda 84.03%
(FY 2023)
- Net Worth 6.65%
(FY 2023)
- Total Assets 6.74%
(FY 2023)
About Skm Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 7.50 M.
The company currently has active open charges totaling ₹3.40 M. The company has closed loans amounting to ₹4.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shomir Mukherjee and Jharna Mukharjee serve as directors at the Company.
- CIN/LLPIN
U85110KA1987PTC008253
- Company No.
008253
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Mar 1987
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Skm Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jharna Mukharjee  | Managing Director | 23-Mar-1987 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shomir Mukherjee | Director | 22-Oct-2002 | Current |
Financial Performance of Skm Pharma.
Skm Pharma Private Limited,, for the financial year ended 2023, experienced significant reduction in revenue, with a 13.98% decrease. The company also saw a substantial improvement in profitability, with a 185.74% increase in profit. The company's net worth moved up by a moderate rise of 6.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skm Pharma?
In 2023, Skm Pharma had a promoter holding of 100.00%. The company had 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 06 Nov 2023 | ₹2.00 M | Open |
Others Creation Date: 19 Jun 2023 | ₹1.40 M | Open |
Canara Bank Creation Date: 17 Oct 2006 | ₹4.00 Cr | Satisfied |
How Many Employees Work at Skm Pharma?
Unlock and access historical data on people associated with Skm Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skm Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skm Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
